Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ampio Pharmaceuticals stock price, quote, forecast and news

AMPE
US03209T1097
A1JGFU

Price

0.00
Today +/-
+0
Today %
+0 %
P

Ampio Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ampio Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ampio Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ampio Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ampio Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ampio Pharmaceuticals Stock Price History

DateAmpio Pharmaceuticals Price
9/6/20240.00 undefined
9/5/20240.00 undefined
9/4/20240.00 undefined
9/3/20240.00 undefined
8/30/20240.00 undefined
8/29/20240.00 undefined
8/28/20240.00 undefined
8/27/20240.00 undefined
8/26/20240.00 undefined
8/23/20240.00 undefined
8/22/20240.00 undefined
8/21/20240.00 undefined
8/20/20240.00 undefined
8/19/20240.00 undefined
8/16/20240.00 undefined
8/15/20240.00 undefined
8/14/20240.00 undefined
8/13/20240.00 undefined
8/12/20240.00 undefined

Ampio Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ampio Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ampio Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ampio Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ampio Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ampio Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ampio Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ampio Pharmaceuticals’s growth potential.

Ampio Pharmaceuticals Revenue, EBIT and net profit per share

DateAmpio Pharmaceuticals RevenueAmpio Pharmaceuticals EBITAmpio Pharmaceuticals Net Income
2026e0 undefined-15.87 M undefined-81,284.37 undefined
2025e0 undefined-21.55 M undefined-105,450 undefined
2024e0 undefined-29.84 M undefined-139,536 undefined
20230 undefined-9.52 M undefined-8.63 M undefined
20220 undefined-20.38 M undefined-16.34 M undefined
20210 undefined-20.57 M undefined-17.08 M undefined
20200 undefined-15.83 M undefined-15.89 M undefined
20190 undefined-18.58 M undefined-13.63 M undefined
20180 undefined-11.18 M undefined33.99 M undefined
20170 undefined-15.56 M undefined-51.89 M undefined
20160 undefined-17.08 M undefined-19.16 M undefined
20150 undefined-24.17 M undefined-32.01 M undefined
20140 undefined-31.45 M undefined-38.13 M undefined
201350,000 undefined-24.02 M undefined-24.01 M undefined
201250,000 undefined-11.82 M undefined-11.59 M undefined
201120,000 undefined-11.13 M undefined-18.36 M undefined
20100 undefined-6.7 M undefined-8.05 M undefined
20090 undefined-1.51 M undefined-1.51 M undefined
20080 undefined-30,000 undefined-30,000 undefined
20070 undefined-30,000 undefined-30,000 undefined
20060 undefined0 undefined0 undefined

Ampio Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
000000000000000000000
---------------------
---------------------
000000000000000000000
000-1-6-11-11-24-31-24-17-15-11-18-15-20-20-9-29-21-15
---------------------
000-1-8-18-11-24-38-32-19-5133-13-15-17-16-8000
----700.00125.00-38.89118.1858.33-15.79-40.63168.42-164.71-139.3915.3813.33-5.88-50.00---
000505090110130170170180220240440580660750810.11000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ampio Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ampio Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
0000.070.6711.3617.6826.3150.32165.028.227.596.5317.3533.8912.654.09
00010100000000000000
000000000000000000
000000000000000700215
0000.010.060.040.160.130.9413.20.380.220.451.720.971.650.670.51
0000.090.7411.417.8426.4451.2629.25.48.448.048.2518.3235.6113.324.82
000000.080.061.39.959.197.986.8465.754.393.190.260
303030000000000000000
000000000000000000
000007.977.928.238.16000000000
000000000000000000
000000.040.020.040.9120.210.03000000
0.030.030.03008.0989.5719.0121.198.196.8765.754.393.190.260
0.030.030.030.090.7419.4925.8436.0170.2750.3913.5915.3114.041422.7138.813.584.82
                                   
3030301800000101010101020202000
0001.315.9646.0663.6996.94168.11171159.73170.8176.23191.06218.02244.86245.73245.89
-0.01-0.04-0.07-1.76-9.82-28.18-39.77-63.78-101.9-133.91-153.08-204.99-171-184.63-200.53-217.6-233.94-242.53
0000-0.15-0.13-0.09-0.09-0.09-0.09-0.030000000
000000000000000000
0.02-0.01-0.04-0.27-4.0117.7523.8333.0766.1337.016.63-34.185.246.4517.5127.2811.793.36
0.010.020.010.080.660.631.21.93.31.80.712.791.323.950.190.430.11.15
0000.070.55000.520.240.891.371.0300.331.654.71.11.23
00000.40.660.430.050.152.830.060.060.0600000
00.020.060.23.140000000000000
000000000000000000
0.010.040.070.354.751.291.632.473.695.522.143.881.384.281.845.131.22.38
000000000000000000
000000000000000000
000000.430.380.331.136.984.8345.617.413.273.536.420.610
000000.430.380.331.136.984.8345.617.413.273.536.420.610
0.010.040.070.354.751.722.012.84.8212.56.9749.498.797.555.3711.551.812.38
0.030.030.030.080.7419.4725.8435.8770.9549.5113.615.3114.031422.8838.8313.65.74
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ampio Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ampio Pharmaceuticals's financial health and stability.

Assets

Ampio Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ampio Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ampio Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ampio Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200620072008200920102011201220132014201520162017201820192020202120222023
000-1-8-18-11-24-39-33-19-5133-13-15-17-16-8
00000000001,0001,0001,0001,0001,0001,0001,0000
000000000000000000
000010010001-21-12-20
0000491476337-44-410-20
000000000000000000
000000000000000000
000-1-2-9-9-19-30-26-14-11-12-15-14-14-21-8
0000000-1-8000000000
0000000-1-14-1800000000
00000000-5-1700000000
000000000000000000
000020000000000000
000112217306803161216263300
0001319162968213141214253000
00000-2-100210-10-1-1-200
000000000000000000
00000106824-23-1130-11016-21-8
0-0.02-0.04-1.37-2.63-9.21-9.72-20.77-39.41-26.55-14.63-11.48-12.7-15.4-14.79-14.19-21.13-8.56
000000000000000000

Ampio Pharmaceuticals stock margins

The Ampio Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ampio Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ampio Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ampio Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Ampio Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ampio Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ampio Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ampio Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ampio Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ampio Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ampio Pharmaceuticals Margin History

Ampio Pharmaceuticals Gross marginAmpio Pharmaceuticals Profit marginAmpio Pharmaceuticals EBIT marginAmpio Pharmaceuticals Profit margin
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %-48,040 %-48,020 %
20120 %-23,640 %-23,180 %
20110 %-55,650 %-91,800.01 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %

Ampio Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Ampio Pharmaceuticals earnings per share therefore indicates how much revenue Ampio Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ampio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ampio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ampio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ampio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ampio Pharmaceuticals Revenue, EBIT and net profit per share

DateAmpio Pharmaceuticals Sales per ShareAmpio Pharmaceuticals EBIT per shareAmpio Pharmaceuticals Earnings per Share
2026e0 undefined0 undefined-0.07 undefined
2025e0 undefined0 undefined-0.09 undefined
2024e0 undefined0 undefined-0.12 undefined
20230 undefined-11.75 undefined-10.66 undefined
20220 undefined-27.17 undefined-21.79 undefined
20210 undefined-31.17 undefined-25.88 undefined
20200 undefined-27.29 undefined-27.4 undefined
20190 undefined-42.23 undefined-30.98 undefined
20180 undefined-46.58 undefined141.63 undefined
20170 undefined-70.73 undefined-235.86 undefined
20160 undefined-94.89 undefined-106.44 undefined
20150 undefined-142.18 undefined-188.29 undefined
20140 undefined-185 undefined-224.29 undefined
20130.38 undefined-184.77 undefined-184.69 undefined
20120.45 undefined-107.45 undefined-105.36 undefined
20110.22 undefined-123.67 undefined-204 undefined
20100 undefined-134 undefined-161 undefined
20090 undefined-30.2 undefined-30.2 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined

Ampio Pharmaceuticals business model

Ampio Pharmaceuticals Inc is a biopharmaceutical company specialized in developing and marketing novel therapies for various diseases. The company was founded in 2010 and is headquartered in Englewood, Colorado. The history of Ampio Pharmaceuticals began with a goal: to realize the vision of developing innovative therapies that benefit patients. The founding idea focused on the development of a new therapy for osteoarthritis. Over time, however, the company diversified and specialized in the development of drugs for other areas such as diabetes, eye diseases, and pneumonia. Ampio Pharmaceuticals' business model is focused on cutting-edge technologies and scientific knowledge. The company employs an integrative approach that utilizes a variety of techniques, including cell-based therapies, gene therapies, and drug development. The company's core competencies lie in research, development, and marketing of innovative therapy options. Ampio Pharmaceuticals is divided into various business units. For example, the company is engaged in the development of drugs based on AMPio technologies. These compounds form the core of the therapy approaches and have already shown promising results in clinical trials. The company also emphasizes collaboration with partners to expedite the development of new therapy options. Another focus of Ampio Pharmaceuticals is the development of therapies for osteoarthritis. The company has developed a range of therapeutics targeting various aspects of the disease, such as anti-inflammatory agents and substances for joint cartilage regeneration. These therapies aim to alleviate the symptoms of osteoarthritis and provide patients with a higher quality of life. In addition to developing new therapy options, Ampio Pharmaceuticals also conducts clinical trials. These studies are designed to test the efficacy and safety of the developed drugs. Ampio Pharmaceuticals is committed to providing the highest standard of medical care by substantiating the safety and efficacy of their drugs through clinical trials. As a company specialized in drug development, Ampio Pharmaceuticals has launched a number of products on the market. These include Ampion, an injectable therapy for knee osteoarthritis, and Optina, an orally administered drug for the treatment of diabetes-related retinopathy. Overall, Ampio Pharmaceuticals is an innovative company specializing in the development of new therapy options. The company leverages modern technologies and scientific knowledge and aims to improve patients' lives through highly effective therapies. Ampio Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Ampio Pharmaceuticals SWOT Analysis

Strengths

1. Patented technology and intellectual property rights

2. Strong research and development capabilities

3. Diverse and promising product pipeline

4. Established partnerships with key industry players

Weaknesses

1. Limited commercialization experience

2. High dependence on successful clinical trials

3. Relatively small market share compared to competitors

Opportunities

1. Growing demand for innovative pharmaceutical products

2. Expansion into new geographical markets

3. Potential collaboration with larger pharmaceutical companies

4. Increasing government support for healthcare research

Threats

1. Intense competition from established pharmaceutical companies

2. Stringent regulatory requirements for product approval

3. Uncertainties in the reimbursement landscape

4. Potential negative impact of economic downturn on healthcare spending

Ampio Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ampio Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Ampio Pharmaceuticals shares outstanding

The number of shares was Ampio Pharmaceuticals in 2023 — This indicates how many shares 810,110 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ampio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ampio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ampio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ampio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ampio Pharmaceuticals Stock splits

In Ampio Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Ampio Pharmaceuticals.

Ampio Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230 -1.53  (0 %)2023 Q3
6/30/2022-0.41 -0.2  (50.98 %)2022 Q2
3/31/2022-0.41 -0.4  (1.96 %)2022 Q1
12/31/2021-0.41 -0.8  (-96.08 %)2021 Q4
9/30/2021-0.02 -0.02  (1.96 %)2021 Q3
6/30/2021-0.02 -0.02  (1.96 %)2021 Q2
3/31/2021-0.02 -0.02  (1.96 %)2021 Q1
12/31/2020-0.02 -0.01  (50.98 %)2020 Q4
6/30/2020-0.04 -0.02  (50.98 %)2020 Q2
3/31/2020-0.04 -0.04  (1.96 %)2020 Q1
1
2
3

Eulerpool ESG Scorecard© for the Ampio Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

32

👫 Social

37

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ampio Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
1.57561 % HRT Financial LP17,96217,96212/31/2023
0.64807 % The Vanguard Group, Inc.7,3883,40012/31/2023
0.64412 % Buchi (J Kevin)7,3432,3436/9/2023
0.45605 % Stevens (David R)5,1994,7505/12/2023
0.33719 % Martino (Michael A)3,8443,8445/24/2023
0.32219 % Geode Capital Management, L.L.C.3,673012/31/2023
0.27623 % Class VI Family Office, LLC3,1493,14912/31/2023
0.23816 % Morgan Stanley & Co. LLC2,7152,50012/31/2023
0.19991 % Tower Research Capital LLC2,2792,16512/31/2023
0.09132 % Stokely (Daniel G.)1,04104/17/2023
1
2
3
4
5
...
10

Ampio Pharmaceuticals Executives and Management Board

Mr. Michael Martino67
Ampio Pharmaceuticals Chief Executive Officer, Director (since 2021)
Compensation 668,141
Mr. Daniel Stokely59
Ampio Pharmaceuticals Chief Financial Officer, Secretary
Compensation 346,725
Ms. Elizabeth Jobes56
Ampio Pharmaceuticals Independent Director
Compensation 108,909
Mr. J. Kevin Buchi68
Ampio Pharmaceuticals Independent Chairman of the Board
Compensation 99,708
Dr. David Stevens74
Ampio Pharmaceuticals Independent Director
Compensation 65,540
1

Ampio Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer-0,580,040,510,69-0,14-0,18
Sartorius Vz Stock
Sartorius Vz
SupplierCustomer-0,800,050,810,810,640,33
1

Most common questions regarding Ampio Pharmaceuticals

What values and corporate philosophy does Ampio Pharmaceuticals represent?

Ampio Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of innovative therapies for common yet difficult-to-treat medical conditions. The company's corporate philosophy revolves around delivering affordable and accessible medical treatments to patients in need. Ampio Pharmaceuticals Inc values scientific expertise, ethical practices, and a commitment to improving patient outcomes. With a dedication to research and development, Ampio Pharmaceuticals Inc strives to address unmet medical needs and enhance the quality of life for individuals worldwide.

In which countries and regions is Ampio Pharmaceuticals primarily present?

Ampio Pharmaceuticals Inc primarily operates in the United States.

What significant milestones has the company Ampio Pharmaceuticals achieved?

Ampio Pharmaceuticals Inc has achieved several significant milestones. One of the notable accomplishments is the successful completion of clinical trials for their lead drug candidate, Ampion™. This innovative formulation has shown promising results in treating various inflammatory conditions. Additionally, Ampio Pharmaceuticals Inc has secured multiple strategic partnerships and collaborations to further advance their research and development efforts. Their commitment to innovation and dedication to improving patient outcomes have positioned the company as a key player in the biopharmaceutical industry. As Ampio Pharmaceuticals Inc continues to progress, they are actively focused on expanding their portfolio of therapies and delivering groundbreaking solutions to address unmet medical needs.

What is the history and background of the company Ampio Pharmaceuticals?

Ampio Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in the development of novel therapies for prevalent medical conditions. Established in [year], Ampio has documented an impressive history of advancements in the field of pharmaceutical research. With a focus on targeted therapies and innovative drug formulations, the company has played a pivotal role in revolutionizing treatment options for various diseases. Ampio Pharmaceuticals Inc prioritizes the development of therapies that address unmet medical needs, aiming to improve patients' quality of life and overall well-being. Building on its strong research capabilities and dedication to innovation, Ampio continues to make significant contributions to the pharmaceutical industry.

Who are the main competitors of Ampio Pharmaceuticals in the market?

Ampio Pharmaceuticals Inc faces competition from various players in the market, including companies such as Celgene Corporation, Pfizer Inc, Johnson & Johnson, and Bristol Myers Squibb Company.

In which industries is Ampio Pharmaceuticals primarily active?

Ampio Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Ampio Pharmaceuticals?

The business model of Ampio Pharmaceuticals Inc is focused on developing and commercializing therapies to treat prevalent inflammatory conditions. Ampio's primary focus is on developing anti-inflammatory drugs for the treatment of osteoarthritis and diabetic macular edema. The company utilizes its proprietary drug delivery technologies to enhance the efficacy of therapies and improve patient outcomes. Ampio's commitment to research and development, along with strategic partnerships and collaborations, helps drive its mission of improving the lives of patients suffering from inflammatory diseases.

What is the P/E ratio of Ampio Pharmaceuticals 2024?

The Ampio Pharmaceuticals P/E ratio is -0.01.

What is the P/S ratio of Ampio Pharmaceuticals 2024?

The Ampio Pharmaceuticals P/S ratio is 0.

What is the AlleAktien quality score of Ampio Pharmaceuticals?

The AlleAktien quality score for Ampio Pharmaceuticals is 2/10.

What is the revenue of Ampio Pharmaceuticals 2024?

The revenue cannot currently be calculated for Ampio Pharmaceuticals.

How high is the profit of Ampio Pharmaceuticals 2024?

The expected Ampio Pharmaceuticals profit is -139,536 USD.

What is the business model of Ampio Pharmaceuticals

Ampio Pharmaceuticals Inc. is an American biopharmaceutical company specializing in the development of drugs for the treatment of osteoarthritic, inflammatory, and metabolic diseases. The company is headquartered in Englewood, Colorado, and has been listed on the NYSE MKT exchange since 2010. Ampio Pharmaceuticals' business model includes a wide range of products and services aimed at improving the health and well-being of patients. The company has three main divisions: Human Therapeutics, Diagnostic Services, and Animal Health. Under the Human Therapeutics category, Ampio Pharmaceuticals offers various types of drugs for the treatment of arthritis, diabetic retinopathy, and other diseases. One of the company's most well-known products is Ampion, a biologically activated protein with anti-inflammatory and regenerative properties. It is used for the treatment of knee osteoarthritis and has been approved by the FDA for a Phase III clinical trial. In the Diagnostic Services division, Ampio Pharmaceuticals provides various tests for early disease diagnosis. The company has developed a proprietary technology platform for biomarker discovery to facilitate the diagnosis of early stages of cancer and other diseases. Ampio Pharmaceuticals also has a division focused on animal treatment. It offers specialized products to help relieve pain and inflammation in animals. Ampio is currently one of the few companies offering joint and soft tissue treatments for horses. The business model of Ampio Pharmaceuticals is based on continuous research and development of new products, enabling the company to remain competitive in a rapidly changing market. The company collaborates closely with leading medical research institutions and universities to ensure it keeps up with the latest developments in the field. Ampio Pharmaceuticals has also formed international partnerships to distribute its products globally. The company has licensed its products to many global companies for distribution in various countries. Overall, Ampio Pharmaceuticals has a solid business model based on scientific research and a focus on improving patient health. The company is committed to taking a leadership position in the biopharmaceutical industry worldwide by continuously growing and expanding its product portfolio to meet the changing needs of patients.

What is the Ampio Pharmaceuticals dividend?

Ampio Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Ampio Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Ampio Pharmaceuticals or the company does not pay out a dividend.

What is the Ampio Pharmaceuticals ISIN?

The ISIN of Ampio Pharmaceuticals is US03209T1097.

What is the Ampio Pharmaceuticals WKN?

The WKN of Ampio Pharmaceuticals is A1JGFU.

What is the Ampio Pharmaceuticals ticker?

The ticker of Ampio Pharmaceuticals is AMPE.

How much dividend does Ampio Pharmaceuticals pay?

Over the past 12 months, Ampio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ampio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ampio Pharmaceuticals?

The current dividend yield of Ampio Pharmaceuticals is .

When does Ampio Pharmaceuticals pay dividends?

Ampio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ampio Pharmaceuticals?

Ampio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ampio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ampio Pharmaceuticals located?

Ampio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ampio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ampio Pharmaceuticals from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Ampio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Ampio Pharmaceuticals in the year 2023?

In the year 2023, Ampio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ampio Pharmaceuticals pay out the dividend?

The dividends of Ampio Pharmaceuticals are distributed in USD.

All fundamentals about Ampio Pharmaceuticals

Our stock analysis for Ampio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ampio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.